AstraZeneca Faslodex survival data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca's breast cancer therapy Faslodex (fulvestrant) is not significantly different from the firm's Arimidex (anastrazole) in the first mature survival data available since approval. Median duration of survival was 27.4 months vs. 27.7 months, respectively. After a median follow-up of 27.2 months, 75% of Faslodex patients vs. 76% of Arimidex patients had died of any cause. The data, presented Dec. 5 at the San Antonio Breast Cancer Symposium, are based on two Phase III trials in a total of 851 postmenopausal women with advanced breast cancer with progression following antiestrogen treatment. AstraZeneca is currently enrolling patients in its 650-patient EFECT study (Evaluation of Faslodex vs. Exemestane Clinical Trial) to compare Faslodex to Pfizer's Aromasin in postmenopausal women with hormone receptor-positive metastatic breast cancer...